Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Can Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5521-3335; OpenAlex author ID A5100447862. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. BE-43547A2 exerts hypoxia-selective inhibition on human pancreatic cancer cells through targeting eEF1A1 and disrupting its association with FoxO1. Co-author DOI 10.1038/s41401-024-01461-y↗
  2. Probe Synthesis Reveals Eukaryotic Translation Elongation Factor 1 Alpha 1 as the Anti-Pancreatic Cancer Target of BE-43547A2. Co-author DOI 10.1002/anie.202206953↗
  3. Corrigendum: Probe Synthesis Reveals Eukaryotic Translation Elongation Factor 1 Alpha 1 as the Anti-Pancreatic Cancer Target of BE-43547A2. Co-author DOI 10.1002/anie.202211687↗
  4. Potential use of aptamers for diagnosis and treatment of pancreatic cancer. First author DOI 10.1080/1061186x.2018.1564924↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yue Chen · 3 shared papers, 2022–2025 · strength 0.54
  2. Yahui Ding · 2 shared papers, 2022–2025 · strength 0.39
  3. Yuanjun Sun · 2 shared papers, 2022 · strength 0.29
  4. Tianyang Chen · 1 shared paper, 2022 · strength 0.15
  5. Juewen Liu · 1 shared paper, 2019 · strength 0.11
  6. Ge Gao · 1 shared paper, 2019 · strength 0.11
  7. Hai Wang · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.